Jun 2026 (Q2 FY26) — Aug 6, 2026
Apyx Medical Q2 FY26 — AYON Platform Drives Strong Growth and Expanded Capabilities
Read the full callApyx Medical (APYX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Apyx Medical earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 13.9 | +22.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -13.0 | +9.6 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -3.2 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$2.56 −0.39% · −$0.01
Performance −24.7% 1Y
1Y: $3.4 on 14 Oct 2025 → $2.56. High $4.86 (9 Jun 2026), low $2.36 (8 Oct 2026).
- Previous close
- $2.57
- 52-week range
- $2.36 – $4.86
- One year
- −17.68%
Overview
- Symbol
- APYX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Apyx Medical earnings calls (APYX)
Financials
What the filings say
Net profit, year on year: +14% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 11 | 14 | 9 | 11 | 13 | 19 | 12 | 14 |
| Operating profit | -4 | -3 | -3 | -3 | -1 | 0 | -1 | -2 |
| Operating margin | −31.6% | −21.4% | −32.4% | −22.6% | −6.5% | 0.1% | −7.3% | −13.0% |
| Other income | -1 | -2 | -1 | -1 | -1 | -1 | -1 | -1 |
| Interest | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | -5 | -5 | -4 | -4 | -2 | -1 | -2 | -3 |
| Tax rate | −1.3% | −1.9% | −1.2% | −1.3% | −4.2% | −8.2% | −7.2% | −4.2% |
| Net profit | -5 | -5 | -4 | -4 | -2 | -1 | -2 | -3 |
| EPS ($ per share) | -0.14 | — | -0.10 | -0.09 | -0.05 | — | -0.05 | -0.07 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 34 | 15 | 3 | -13 | -36 | -54 | -78 | -89 |
| Total liabilities | 9 | 13 | 10 | 15 | 14 | 52 | 51 | 52 |
| Fixed assets | 6 | 7 | 7 | 7 | 7 | 2 | 2 | 2 |
| Investments | 62 | 57 | 40 | — | — | — | — | — |
| Total assets | 96 | 85 | 74 | 69 | 52 | 79 | 65 | 67 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -21 | -18 | -16 | -10 | -20 | -5 | -18 | -8 |
| Cash from investing | 29 | 61 | -1 | -1 | -1 | 7 | -1 | -1 |
| Cash from financing | -2 | 0 | -0 | 0 | 0 | 32 | 7 | 10 |
| Net cash flow | 6 | 42 | -17 | -11 | -21 | 33 | -12 | -0 |
| Capital expenditure | -0 | -1 | -1 | -1 | -1 | -1 | -1 | -1 |
| Free cash flow | -21 | -20 | -17 | -11 | -21 | -6 | -19 | -9 |
Insider filings
7 filings between Jan 27, 2026 and Jun 30, 2026.
Open market
decisions to buy or sellNobody bought or sold APYX on the open market in this window. The filings below are 1 award, 4 option exercises and 2 tax withholdings.
Compensation
not trading decisions- 1
- Award — granted as compensation
- 4
- Option exercise — converted options into shares
- 2
- Tax withheld — shares kept back by the company to cover tax
Latest filings (8)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 30, 2026 | Waldman Lawrence Director | Option exercise | 12,000 | $22.6K |
| Jun 30, 2026 | Waldman Lawrence Director | Tax withheld | 5,024 | $22.6K |
| Jun 15, 2026 | Roman Shawn David Chief Operating Officer | Option exercise | 15,000 | $48.5K |
| Jun 15, 2026 | Roman Shawn David Chief Operating Officer | Tax withheld | 10,533 | $48.5K |
| Jun 11, 2026 | Vizirgianakis Stavros G. Director | Award | 450,000 | $0 |
| Mar 15, 2026 | CITRONOWICZ MOSHE Senior Vice President | Option exercise | 37,000 | $66.6K |
| Jan 27, 2026 | Roman Shawn David Chief Operating Officer | Option exercise | 12,000 | $21.6K |
| Aug 13, 2024 | HILL MATTHEW C Chief Financial Officer | Purchase | 6,000 | $6.8K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Apyx Medical Corp
Free account. Everything above stays public.
Write why you follow Apyx Medical Corp and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading